Ajay Piramal says liquidity isn't a problem for good NBFCs

Piramal sees a 'U' shaped one, which is more gradual than a 'V' shaped recovery

Viswanath Pilla

July 10, 2020 / 08:29 PM IST

Image: Moneycontrol

live

bselive
nselive

Volume

Todays L/H

Ajay Piramal, Chairman of Piramal Enterprises, on July 10 said the measures taken by the Reserve Bank of India (RBI) and banks have improved liquidity in system.

Speaking at 7th SBI Baking and Economic Conclave, he said it is only investment grade non-banking financial companies (NBFCs) under AAA and AA category that are getting funding, the other ones are still suffering.

"It's only the public sector banks that stood up to meet the funding requirements. Earlier mutual funds and private banks used to provide liquidity- now it is only public sector banks (PSBs)," he stated.

Piramal said more than solvency, it is liquidity that's critical at the moment.

Commenting on the real estate space, Piramal said the biggest challenge is generating demand. "Reducing prices are not going to make a difference. Demand has to be generated. People have to have confidence to invest. We have to ensure supportive measures like speeding up permissions for real estate projects and making liquidity available."

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show